Cargando…
Fatigue following radiotherapy of low-risk early breast cancer – a randomized controlled trial of intraoperative electron radiotherapy versus standard hypofractionated whole-breast radiotherapy: the COSMOPOLITAN trial (NCT03838419)
BACKGROUND: Fatigue is one of the most common and distressing side-effects of breast cancer radiotherapy. According to current guidelines, accelerated partial breast irradiation (APBI) may be considered as an alternative treatment option for women with early-stage low-risk breast cancer. One method...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7268450/ https://www.ncbi.nlm.nih.gov/pubmed/32487184 http://dx.doi.org/10.1186/s13014-020-01581-9 |
_version_ | 1783541619049365504 |
---|---|
author | Forster, Tobias Jäkel, Cornelia Akbaba, Sati Krug, David Krempien, Robert Uhl, Matthias Häfner, Matthias Felix König, Laila Koerber, Stefan Alexander Harrabi, Semi Bernhardt, Denise Behnisch, Rouven Krisam, Johannes Hennigs, Andre Sohn, Christof Heil, Jörg Debus, Jürgen Hörner-Rieber, Juliane |
author_facet | Forster, Tobias Jäkel, Cornelia Akbaba, Sati Krug, David Krempien, Robert Uhl, Matthias Häfner, Matthias Felix König, Laila Koerber, Stefan Alexander Harrabi, Semi Bernhardt, Denise Behnisch, Rouven Krisam, Johannes Hennigs, Andre Sohn, Christof Heil, Jörg Debus, Jürgen Hörner-Rieber, Juliane |
author_sort | Forster, Tobias |
collection | PubMed |
description | BACKGROUND: Fatigue is one of the most common and distressing side-effects of breast cancer radiotherapy. According to current guidelines, accelerated partial breast irradiation (APBI) may be considered as an alternative treatment option for women with early-stage low-risk breast cancer. One method for APBI is single-dose intraoperative radiotherapy (IORT) applied directly to the tumor bed during breast conserving surgery (BCS). The COSMOPOLITAN trial therefore aims to analyze the intensity of fatigue following single-shot IORT with electrons (IOERT) compared to conventional hypofractionated whole breast irradiation (WBI) in low risk early breast cancer patients. METHODS: This trial is conducted as a multicenter, prospective, randomized, two-arm phase II study comparing the intensity of fatigue in early-stage breast cancer (cT1cN0cM0, tumor size < 2,5 cm, ER pos. Her2neu neg., age > 50 years) treated either with WBI or APBI after BCS. Secondary outcomes investigated are tumor control, overall survival (OS), disease-free survival (DFS), acute and chronic toxicity, quality of life (QoL) and cosmesis. A total of 202 patients will be randomized into two arms: Patients in arm A will receive WBI (40.05 Gy, 15 fractions) after surgical resection, while patients in arm B will receive IOERT (21 Gy to the 90%-isodose) during BCS. Fatigue will be assessed 12 weeks post surgery with the help of the Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale. DISCUSSION: The present trial aims to evaluate treatment response to compare single-shot intraoperative electron APBI to conventional WBI following BCS in early-stage low risk breast cancer patients. Fatigue is selected as the primary, patient-reported endpoint due its major clinical relevance. TRIAL REGISTRATION: The study is prospectively registered on February 12th, 2019: Clinicaltrials.gov, NCT03838419. “Intraoperative Electron Radiotherapy for Low-risk Early Breast Cancer (COSMOPOLITAN)”. STUDY STATUS: Ongoing study. Start of recruitment was December 2019. |
format | Online Article Text |
id | pubmed-7268450 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-72684502020-06-07 Fatigue following radiotherapy of low-risk early breast cancer – a randomized controlled trial of intraoperative electron radiotherapy versus standard hypofractionated whole-breast radiotherapy: the COSMOPOLITAN trial (NCT03838419) Forster, Tobias Jäkel, Cornelia Akbaba, Sati Krug, David Krempien, Robert Uhl, Matthias Häfner, Matthias Felix König, Laila Koerber, Stefan Alexander Harrabi, Semi Bernhardt, Denise Behnisch, Rouven Krisam, Johannes Hennigs, Andre Sohn, Christof Heil, Jörg Debus, Jürgen Hörner-Rieber, Juliane Radiat Oncol Study Protocol BACKGROUND: Fatigue is one of the most common and distressing side-effects of breast cancer radiotherapy. According to current guidelines, accelerated partial breast irradiation (APBI) may be considered as an alternative treatment option for women with early-stage low-risk breast cancer. One method for APBI is single-dose intraoperative radiotherapy (IORT) applied directly to the tumor bed during breast conserving surgery (BCS). The COSMOPOLITAN trial therefore aims to analyze the intensity of fatigue following single-shot IORT with electrons (IOERT) compared to conventional hypofractionated whole breast irradiation (WBI) in low risk early breast cancer patients. METHODS: This trial is conducted as a multicenter, prospective, randomized, two-arm phase II study comparing the intensity of fatigue in early-stage breast cancer (cT1cN0cM0, tumor size < 2,5 cm, ER pos. Her2neu neg., age > 50 years) treated either with WBI or APBI after BCS. Secondary outcomes investigated are tumor control, overall survival (OS), disease-free survival (DFS), acute and chronic toxicity, quality of life (QoL) and cosmesis. A total of 202 patients will be randomized into two arms: Patients in arm A will receive WBI (40.05 Gy, 15 fractions) after surgical resection, while patients in arm B will receive IOERT (21 Gy to the 90%-isodose) during BCS. Fatigue will be assessed 12 weeks post surgery with the help of the Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale. DISCUSSION: The present trial aims to evaluate treatment response to compare single-shot intraoperative electron APBI to conventional WBI following BCS in early-stage low risk breast cancer patients. Fatigue is selected as the primary, patient-reported endpoint due its major clinical relevance. TRIAL REGISTRATION: The study is prospectively registered on February 12th, 2019: Clinicaltrials.gov, NCT03838419. “Intraoperative Electron Radiotherapy for Low-risk Early Breast Cancer (COSMOPOLITAN)”. STUDY STATUS: Ongoing study. Start of recruitment was December 2019. BioMed Central 2020-06-01 /pmc/articles/PMC7268450/ /pubmed/32487184 http://dx.doi.org/10.1186/s13014-020-01581-9 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Study Protocol Forster, Tobias Jäkel, Cornelia Akbaba, Sati Krug, David Krempien, Robert Uhl, Matthias Häfner, Matthias Felix König, Laila Koerber, Stefan Alexander Harrabi, Semi Bernhardt, Denise Behnisch, Rouven Krisam, Johannes Hennigs, Andre Sohn, Christof Heil, Jörg Debus, Jürgen Hörner-Rieber, Juliane Fatigue following radiotherapy of low-risk early breast cancer – a randomized controlled trial of intraoperative electron radiotherapy versus standard hypofractionated whole-breast radiotherapy: the COSMOPOLITAN trial (NCT03838419) |
title | Fatigue following radiotherapy of low-risk early breast cancer – a randomized controlled trial of intraoperative electron radiotherapy versus standard hypofractionated whole-breast radiotherapy: the COSMOPOLITAN trial (NCT03838419) |
title_full | Fatigue following radiotherapy of low-risk early breast cancer – a randomized controlled trial of intraoperative electron radiotherapy versus standard hypofractionated whole-breast radiotherapy: the COSMOPOLITAN trial (NCT03838419) |
title_fullStr | Fatigue following radiotherapy of low-risk early breast cancer – a randomized controlled trial of intraoperative electron radiotherapy versus standard hypofractionated whole-breast radiotherapy: the COSMOPOLITAN trial (NCT03838419) |
title_full_unstemmed | Fatigue following radiotherapy of low-risk early breast cancer – a randomized controlled trial of intraoperative electron radiotherapy versus standard hypofractionated whole-breast radiotherapy: the COSMOPOLITAN trial (NCT03838419) |
title_short | Fatigue following radiotherapy of low-risk early breast cancer – a randomized controlled trial of intraoperative electron radiotherapy versus standard hypofractionated whole-breast radiotherapy: the COSMOPOLITAN trial (NCT03838419) |
title_sort | fatigue following radiotherapy of low-risk early breast cancer – a randomized controlled trial of intraoperative electron radiotherapy versus standard hypofractionated whole-breast radiotherapy: the cosmopolitan trial (nct03838419) |
topic | Study Protocol |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7268450/ https://www.ncbi.nlm.nih.gov/pubmed/32487184 http://dx.doi.org/10.1186/s13014-020-01581-9 |
work_keys_str_mv | AT forstertobias fatiguefollowingradiotherapyoflowriskearlybreastcancerarandomizedcontrolledtrialofintraoperativeelectronradiotherapyversusstandardhypofractionatedwholebreastradiotherapythecosmopolitantrialnct03838419 AT jakelcornelia fatiguefollowingradiotherapyoflowriskearlybreastcancerarandomizedcontrolledtrialofintraoperativeelectronradiotherapyversusstandardhypofractionatedwholebreastradiotherapythecosmopolitantrialnct03838419 AT akbabasati fatiguefollowingradiotherapyoflowriskearlybreastcancerarandomizedcontrolledtrialofintraoperativeelectronradiotherapyversusstandardhypofractionatedwholebreastradiotherapythecosmopolitantrialnct03838419 AT krugdavid fatiguefollowingradiotherapyoflowriskearlybreastcancerarandomizedcontrolledtrialofintraoperativeelectronradiotherapyversusstandardhypofractionatedwholebreastradiotherapythecosmopolitantrialnct03838419 AT krempienrobert fatiguefollowingradiotherapyoflowriskearlybreastcancerarandomizedcontrolledtrialofintraoperativeelectronradiotherapyversusstandardhypofractionatedwholebreastradiotherapythecosmopolitantrialnct03838419 AT uhlmatthias fatiguefollowingradiotherapyoflowriskearlybreastcancerarandomizedcontrolledtrialofintraoperativeelectronradiotherapyversusstandardhypofractionatedwholebreastradiotherapythecosmopolitantrialnct03838419 AT hafnermatthiasfelix fatiguefollowingradiotherapyoflowriskearlybreastcancerarandomizedcontrolledtrialofintraoperativeelectronradiotherapyversusstandardhypofractionatedwholebreastradiotherapythecosmopolitantrialnct03838419 AT koniglaila fatiguefollowingradiotherapyoflowriskearlybreastcancerarandomizedcontrolledtrialofintraoperativeelectronradiotherapyversusstandardhypofractionatedwholebreastradiotherapythecosmopolitantrialnct03838419 AT koerberstefanalexander fatiguefollowingradiotherapyoflowriskearlybreastcancerarandomizedcontrolledtrialofintraoperativeelectronradiotherapyversusstandardhypofractionatedwholebreastradiotherapythecosmopolitantrialnct03838419 AT harrabisemi fatiguefollowingradiotherapyoflowriskearlybreastcancerarandomizedcontrolledtrialofintraoperativeelectronradiotherapyversusstandardhypofractionatedwholebreastradiotherapythecosmopolitantrialnct03838419 AT bernhardtdenise fatiguefollowingradiotherapyoflowriskearlybreastcancerarandomizedcontrolledtrialofintraoperativeelectronradiotherapyversusstandardhypofractionatedwholebreastradiotherapythecosmopolitantrialnct03838419 AT behnischrouven fatiguefollowingradiotherapyoflowriskearlybreastcancerarandomizedcontrolledtrialofintraoperativeelectronradiotherapyversusstandardhypofractionatedwholebreastradiotherapythecosmopolitantrialnct03838419 AT krisamjohannes fatiguefollowingradiotherapyoflowriskearlybreastcancerarandomizedcontrolledtrialofintraoperativeelectronradiotherapyversusstandardhypofractionatedwholebreastradiotherapythecosmopolitantrialnct03838419 AT hennigsandre fatiguefollowingradiotherapyoflowriskearlybreastcancerarandomizedcontrolledtrialofintraoperativeelectronradiotherapyversusstandardhypofractionatedwholebreastradiotherapythecosmopolitantrialnct03838419 AT sohnchristof fatiguefollowingradiotherapyoflowriskearlybreastcancerarandomizedcontrolledtrialofintraoperativeelectronradiotherapyversusstandardhypofractionatedwholebreastradiotherapythecosmopolitantrialnct03838419 AT heiljorg fatiguefollowingradiotherapyoflowriskearlybreastcancerarandomizedcontrolledtrialofintraoperativeelectronradiotherapyversusstandardhypofractionatedwholebreastradiotherapythecosmopolitantrialnct03838419 AT debusjurgen fatiguefollowingradiotherapyoflowriskearlybreastcancerarandomizedcontrolledtrialofintraoperativeelectronradiotherapyversusstandardhypofractionatedwholebreastradiotherapythecosmopolitantrialnct03838419 AT hornerrieberjuliane fatiguefollowingradiotherapyoflowriskearlybreastcancerarandomizedcontrolledtrialofintraoperativeelectronradiotherapyversusstandardhypofractionatedwholebreastradiotherapythecosmopolitantrialnct03838419 |